Incyte Corporation is a pharmaceutical company that focuses on the discovery, development, and commercialization of novel medicines to address unmet medical needs.
The company was founded in 1991 and is headquartered in Wilmington, Delaware, in the United States.
Incyte has research and development operations located in the US, Europe, and China, and has developed a number of drugs that are focused on the treatment of various cancers, autoimmune disorders, and other diseases.
One of the company’s most well-known drugs is Jakafi (ruxolitinib), which is used to treat patients with myelofibrosis, a type of bone marrow cancer.
In addition to Jakafi, Incyte is also developing a number of other compounds, including baricitinib (currently marketed in collaboration with Eli Lilly and Company), an oral JAK1/JAK2 inhibitor used to treat rheumatoid arthritis and other inflammatory diseases.
Incyte is committed to supporting the healthcare community and advancing the understanding of diseases and therapies through various educational and scientific initiatives.